Vitamin D and breast cancer: Inhibition of estrogen synthesis and signaling

Journal of Steroid Biochemistry and Molecular Biology

Volumn 121, Issue 1-2, 2010, Pages 343-348

  Krishnan, Aruna V ^a   Swami, Srilatha ^a   Feldman, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

15 PGDH; Anti proliferative effects; Aromatase; Aromatase inhibitors; Breast cancer; Calcitriol; COX 2; Prostaglandins

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; AROMATASE; CALCITRIOL; CYCLOOXYGENASE 2; PROSTAGLANDIN E2; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; ANTIESTROGEN; ESTROGEN; VITAMIN D;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; DOWN REGULATION; ENZYME INHIBITION; ESTROGEN METABOLISM; GENETIC TRANSCRIPTION; HORMONE INHIBITION; HUMAN; NONHUMAN; PROSTAGLANDIN BLOOD LEVEL; PROSTAGLANDIN METABOLISM; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ADIPOSE TISSUE; ANIMAL; APOPTOSIS; BREAST; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ADIPOSE TISSUE; ANIMALS; APOPTOSIS; BREAST; BREAST NEOPLASMS; CALCITRIOL; CYCLOOXYGENASE 2; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; VITAMIN D;

EID: 77954760178     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2010.02.009     Document Type: Article

References (76)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58(2):71-96.
2. Althuis M.D., Fergenbaum J.H., Garcia-Closas M., Brinton L.A., Madigan M.P., Sherman M.E. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol. Biomarkers Prev. 2004, 13(10):1558-1568.
3. Feldman D., Malloy P.J., Krishnan A.V., Balint E. Vitamin D: biology, action and clinical implications. Osteoporosis 2007, vol. 1:317-382. Academic Press, San Diego. third ed.
4. Beer T.M., Myrthue A. Calcitriol in cancer treatment: from the lab to the clinic. Mol. Cancer Ther. 2004, 3(3):373-381.
5. Colston K., Welsh J. Vitamin D and breast cancer. Vitamin D 2005, vol. 2:1663-1677. Elsevier Academic Press, San Diego. second ed.
6. Colston K.W., Hansen C.M. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr. Relat. Cancer 2002, 9(1):45-59.
7. Harris D.M., Go V.L. Vitamin D and colon carcinogenesis. J. Nutr. 2004, 134(Suppl. 12):3463S-3471S.
8. Krishnan A.V., Moreno J., Nonn L., Swami S., Peehl D.M., Feldman D. Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. J. Bone Miner. Res. 2007, 22(Suppl. 2):V74-V80.
9. Luong Q.T., Koeffler H.P. Vitamin D compounds in leukemia. J. Steroid Biochem. Mol. Biol. 2005, 97(1-2):195-202.
10. Trump D.L., Muindi J., Fakih M., Yu W.D., Johnson C.S. Vitamin D compounds: clinical development as cancer therapy and prevention agents. Anticancer Res. 2006, 26(4A):2551-2556.
11. Welsh J. Targets of vitamin D receptor signaling in the mammary gland. J. Bone Miner. Res. 2007, 22(Suppl. 2):V86-V90.
12. Garland C.F., Gorham E.D., Mohr S.B., Grant W.B., Giovannucci E.L., Lipkin M., Newmark H., Holick M.F., Garland F.C. Vitamin D and prevention of breast cancer: pooled analysis. J. Steroid Biochem. Mol. Biol. 2007, 103(3-5):708-711.
13. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr. Rev. 2001, 22(4):477-501.
14. Giovannucci E. Vitamin D status and cancer incidence and mortality. Adv. Exp. Med. Biol. 2008, 624:31-42.
15. Welsh J., Wietzke J.A., Zinser G.M., Byrne B., Smith K., Narvaez C.J. Vitamin D-3 receptor as a target for breast cancer prevention. J. Nutr. 2003, 133(Suppl. 7):2425S-2433S.
16. Narvaez C.J., Zinser G., Welsh J. Functions of 1alpha, 25-dihydroxyvitamin D(3) in mammary gland: from normal development to breast cancer. Steroids 2001, 66(3-5):301-308.
17. Escaleira M.T., Brentani M.M. Vitamin D3 receptor (VDR) expression in HC-11 mammary cells: regulation by growth-modulatory agents, differentiation, and Ha-ras transformation. Breast Cancer Res. Treat. 1999, 54(2):123-133.
18. Lazzaro G., Agadir A., Qing W., Poria M., Mehta R.R., Moriarty R.M., Das Gupta T.K., Zhang X.K., Mehta R.G. Induction of differentiation by 1alpha-hydroxyvitamin D(5) in T47D human breast cancer cells and its interaction with vitamin D receptors. Eur. J. Cancer 2000, 36(6):780-786.
19. Gross C., Stamey T., Hancock S., Feldman D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J. Urol. 1998, 159(6):2035-2039. discussion 2039-2040.
20. Bower M., Colston K.W., Stein R.C., Hedley A., Gazet J.C., Ford H.T., Combes R.C. Topical calcipotriol treatment in advanced breast cancer. Lancet 1991, 337(8743):701-702.
21. Gulliford T., English J., Colston K.W., Menday P., Moller S., Coombes R.C. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br. J. Cancer 1998, 78(1):6-13.
22. Hansen C.M., Hamberg K.J., Binderup E., Binderup L. Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. Curr. Pharm. Des. 2000, 6(7):803-828.
23. Group T.W.s.H.I.S. Design of the Women's Health Initiative clinical trial and observational study. Control. Clin. Trials 1998, 19(1):61-109. The Women's Health Initiative Study Group.
24. Wactawski-Wende J., Kotchen J.M., Anderson G.L., Assaf A.R., Brunner R.L., O'Sullivan M.J., Margolis K.L., Ockene J.K., Phillips L., Pottern L., Prentice R.L., Robbins J., Rohan T.E., Sarto G.E., Sharma S., Stefanick M.L., Van Horn L., Wallace R.B., Whitlock E., Bassford T., Beresford S.A., Black H.R., Bonds D.E., Brzyski R.G., Caan B., Chlebowski R.T., Cochrane B., Garland C., Gass M., Hays J., Heiss G., Hendrix S.L., Howard B.V., Hsia J., Hubbell F.A., Jackson R.D., Johnson K.C., Judd H., Kooperberg C.L., Kuller L.H., LaCroix A.Z., Lane D.S., Langer R.D., Lasser N.L., Lewis C.E., Limacher M.C., Manson J.E. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N. Engl. J. Med. 2006, 354(7):684-696.
25. Ding E.L., Mehta S., Fawzi W.W., Giovannucci E.L. Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women's Health Initiative randomized trial. Int. J. Cancer 2008, 122(8):1690-1694.
26. Welsh J., Wietzke J.A., Zinser G.M., Smyczek S., Romu S., Tribble E., Welsh J.C., Byrne B., Narvaez C.J. Impact of the vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer. J. Steroid Biochem. Mol. Biol. 2002, 83(1-5):85-92.
27. Fan F.S., Yu W.C. 1,25-Dihydroxyvitamin D3 suppresses cell growth, DNA synthesis, and phosphorylation of retinoblastoma protein in a breast cancer cell line. Cancer Invest. 1995, 13(3):280-286.
28. Jensen S.S., Madsen M.W., Lukas J., Binderup L., Bartek J. Inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol. Endocrinol. 2001, 15(8):1370-1380.
29. Simboli-Campbell M., Narvaez C.J., van Weelden K., Tenniswood M., Welsh J. Comparative effects of 1, 25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res. Treat. 1997, 42(1):31-41.
30. Pendas-Franco N., Gonzalez-Sancho J.M., Suarez Y., Aguilera O., Steinmeyer A., Gamallo C., Berciano M.T., Lafarga M., Munoz A. Vitamin D regulates the phenotype of human breast cancer cells. Differentiation 2007, 75(3):193-207.
31. Wang Q., Lee D., Sysounthone V., Chandraratna R.A.S., Christakos S., Korah R., Wieder R. 1,25-Dihydroxyvitamin D3 and retinoic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects. Breast Cancer Res. Treat. 2001, 67(2):157-168.
32. James S.Y., Mackay A.G., Colston K.W. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J. Steroid Biochem. Mol. Biol. 1996, 58(4):395-401.
33. Simboli-Campbell M., Narvaez C.J., Tenniswood M., Welsh J. 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J. Steroid Biochem. Mol. Biol. 1996, 58(4):367-376.
34. Narvaez C.J., Welsh J. Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J. Biol. Chem. 2001, 276(12):9101-9107.
35. Pirianov G., Colston K.W. Interactions of vitamin D analogue CB1093, TNFalpha and ceramide on breast cancer cell apoptosis. Mol. Cell. Endocrinol. 2001, 172(1-2):69-78.
36. Rocker D., Ravid A., Liberman U.A., Garach-Jehoshua O., Koren R. 1,25-Dihydroxyvitamin D3 potentiates the cytotoxic effect of TNF on human breast cancer cells. Mol. Cell. Endocrinol. 1994, 106(1-2):157-162.
37. Flanagan L., Packman K., Juba B., O'Neill S., Tenniswood M., Welsh J. Efficacy of vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion. J. Steroid Biochem. Mol. Biol. 2003, 84(2-3):181-192.
38. Hansen C.M., Frandsen T.L., Brunner N., Binderup L. 1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin. Exp. Metastasis 1994, 12(3):195-202.
39. Koli K., Keski-Oja J. 1alpha,25-Dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ. 2000, 11(4):221-229.
40. Allavena P., Garlanda C., Borrello M.G., Sica A., Mantovani A. Pathways connecting inflammation and cancer. Curr. Opin. Genet. Dev. 2008, 18(1):3-10.
41. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454(7203):436-444.
42. Lucia M.S., Torkko K.C. Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. J. Urol. 2004, 171(2 Pt 2):S30-S34. discussion S35.
43. Mantovani A., Pierotti M.A. Cancer and inflammation: a complex relationship. Cancer Lett. 2008, 267(2):180-181.
44. Angelo L.S., Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin. Cancer Res. 2007, 13(10):2825-2830.
45. Kundu J.K., Surh Y.J. Inflammation: gearing the journey to cancer. Mutat. Res. 2008, 659(1-2):15-30.
46. Krishnan A.V., Moreno J., Nonn L., Malloy P., Swami S., Peng L., Peehl D.M., Feldman D. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J. Steroid Biochem. Mol. Biol. 2007, 103(3-5):694-702.
47. Moreno J., Krishnan A.V., Swami S., Nonn L., Peehl D.M., Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res. 2005, 65(17):7917-7925.
48. Nonn L., Peng L., Feldman D., Peehl D.M. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res. 2006, 66(8):4516-4524.
49. Krishnan A.V., Swami S., Peng L., Wang J., Moreno J., Feldman D. Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology 2010, 15(1):32-42.
50. Wang D., Dubois R.N. Cyclooxygenase-2: a potential target in breast cancer. Semin. Oncol. 2004, 31(1 Suppl. 3):64-73.
51. Ristimaki A., Sivula A., Lundin J., Lundin M., Salminen T., Haglund C., Joensuu H., Isola J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002, 62(3):632-635.
52. Wolf I., O'Kelly J., Rubinek T., Tong M., Nguyen A., Lin B.T., Tai H.H., Karlan B.Y., Koeffler H.P. 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res. 2006, 66(15):7818-7823.
53. Brodie A.M., Lu Q., Long B.J., Fulton A., Chen T., Macpherson N., DeJong P.C., Blankenstein M.A., Nortier J.W., Slee P.H., van de Ven J., van Gorp J.M., Elbers J.R., Schipper M.E., Blijham G.H., Thijssen J.H. Aromatase and COX-2 expression in human breast cancers. J. Steroid Biochem. Mol. Biol. 2001, 79(1-5):41-47.
54. Brueggemeier R.W., Quinn A.L., Parrett M.L., Joarder F.S., Harris R.E., Robertson F.M. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett. 1999, 140(1-2):27-35.
55. Chen S. Aromatase and breast cancer. Front. Biosci. 1998, 3:d922-d933.
56. Brodie A., Long B., Lu Q. Aromatase expression in the human breast. Breast Cancer Res. Treat. 1998, 49(Suppl. 1):S85-S91. discussion S109-S119.
57. Simpson E.R., Clyne C., Rubin G., Boon W.C., Robertson K., Britt K., Speed C., Jones M. Aromatase-a brief overview. Annu. Rev. Physiol. 2002, 64:93-127.
58. Enjuanes A., Garcia-Giralt N., Supervia A., Nogues X., Mellibovsky L., Carbonell J., Grinberg D., Balcells S., Diez-Perez A. Regulation of CYP19 gene expression in primary human osteoblasts: effects of vitamin D and other treatments. Eur. J. Endocrinol. 2003, 148(5):519-526.
59. Yanase T., Suzuki S., Goto K., Nomura M., Okabe T., Takayanagi R., Nawata H. Aromatase in bone: roles of vitamin D3 and androgens. J. Steroid Biochem. Mol. Biol. 2003, 86(3-5):393-397.
60. Hughes S.V., Robinson E., Bland R., Lewis H.M., Stewart P.M., Hewison M. 1,25-Dihydroxyvitamin D3 regulates estrogen metabolism in cultured keratinocytes. Endocrinology 1997, 138(9):3711-3718.
61. Lou Y.R., Murtola T., Tuohimaa P. Regulation of aromatase and 5alpha-reductase by 25-hydroxyvitamin D(3), 1alpha,25-dihydroxyvitamin D(3), dexamethasone and progesterone in prostate cancer cells. J. Steroid Biochem. Mol. Biol. 2005, 94(1-3):151-157.
62. Zhou D., Chen S. Identification and characterization of a cAMP-responsive element in the region upstream from promoter 1.3 of the human aromatase gene. Arch. Biochem. Biophys. 1999, 371(2):179-190.
63. Diaz-Cruz E.S., Shapiro C.L., Brueggemeier R.W. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J. Clin. Endocrinol. Metab. 2005, 90(5):2563-2570.
64. Zhao Y., Agarwal V.R., Mendelson C.R., Simpson E.R. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996, 137(12):5739-5742.
65. Davies G.L. Cyclooxygenase-2 and chemoprevention of breast cancer. J. Steroid Biochem. Mol. Biol. 2003, 86(3-5):495-499.
66. Brueggemeier R.W. Update on the use of aromatase inhibitors in breast cancer. Expert Opin. Pharmacother. 2006, 7(14):1919-1930.
67. Geisler J., Lonning P.E. Aromatase inhibition: translation into a successful therapeutic approach. Clin. Cancer Res. 2005, 11(8):2809-2821.
68. Wheler J., Johnson M., Seidman A. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy. Semin. Oncol. 2006, 33(6):672-680.
69. Confavreux C.B., Fontana A., Guastalla J.P., Munoz F., Brun J., Delmas P.D. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 2007, 41(3):346-352.
70. Mincey B.A., Duh M.S., Thomas S.K., Moyneur E., Marynchencko M., Boyce S.P., Mallett D., Perez E.A. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin. Breast Cancer 2006, 7(2):127-132.
71. Jordan C. Historical perspective on hormonal therapy of advanced breast cancer. Clin. Ther. 2002, 24(Suppl. A):A3-A16.
72. Swami S., Krishnan A.V., Feldman D. 1alpha, 25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin. Cancer Res. 2000, 6(8):3371-3379.
73. James S.Y., Mackay A.G., Binderup L., Colston K.W. Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells. J. Endocrinol. 1994, 141(3):555-563.
74. Stoica A., Saceda M., Fakhro A., Solomon H.B., Fenster B.D., Martin M.B. Regulation of estrogen receptor-alpha gene expression by 1,25-dihydroxyvitamin D in MCF-7 cells. J. Cell. Biochem. 1999, 75(4):640-651.
75. Abe-Hashimoto J., Kikuchi T., Matsumoto T., Nishii Y., Ogata E., Ikeda K. Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res. 1993, 53(11):2534-2537.
76. Vink-van Wijngaarden T., Pols H.A., Buurman C.J., van den Bemd G.J., Dorssers L.C., Birkenhager J.C., van Leeuwen J.P. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Res. 1994, 54(21):5711-5717.